Vani Lakshminarayanan

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

Vani Lakshminarayanan, Pamela Thompson, Margreet A. Wolfert et al. · Proceedings of the National Academy of Sciences · 2011 · 300 citations · Full text

Life Sciences, Immunology, Oncology +17

Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist

Abu‐Baker M. Abdel‐Aal, Vani Lakshminarayanan, Pamela Thompson et al. · ChemBioChem · 2014 · 65 citations

Medicine, Immunology, Oncology +17

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

Pamela Thompson, Vani Lakshminarayanan, Nitin T. Supekar et al. · Chemical Communications · 2015 · 61 citations · Full text

Life Sciences, Immunology, Oncology +17

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

Vani Lakshminarayanan, Nitin T. Supekar, Jie Wei et al. · PLoS ONE · 2016 · 53 citations · Full text

Medicine, Immunology, Oncology +17

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Kristen Sweet, Qingxuan Song, Matthew J. Loza et al. · RMD Open · 2021 · 39 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17